Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123,180,519
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
65,162,167
-
Shares change
-
-348,774
-
Total reported value, excl. options
-
$345,106,769
-
Value change
-
-$2,224,745
-
Put/Call ratio
-
3.05%
-
Number of buys
-
58
-
Number of sells
-
-70
-
Price
-
$5.3
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q3 2021
159 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2021.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65,162,167 shares
of 123,180,519 outstanding shares and own 52.9% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (10,000,000 shares), BlackRock Inc. (7,962,533 shares), STATE STREET CORP (6,069,381 shares), LSV ASSET MANAGEMENT (5,259,705 shares), VANGUARD GROUP INC (4,895,853 shares), ROYCE & ASSOCIATES LP (3,006,994 shares), GEODE CAPITAL MANAGEMENT, LLC (1,896,976 shares), DIMENSIONAL FUND ADVISORS LP (1,753,974 shares), PRUDENTIAL FINANCIAL INC (1,655,752 shares), and ACADIAN ASSET MANAGEMENT LLC (1,434,950 shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.